APEX, 2016 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of betrixaban versus enoxaparin in

        Z

NCT01583218    N Engl J Med 2016 May 27;:  



Studied treatment betrixaban (at a dose of 80 mg once daily) for 35 to 42 days
Control treatment subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days



Patients
Group sizes3759 / 3754
DVT diagnosis
PE diagnosis



Blindness double-blind Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism Design Parallel groups



EndpointX1N1X0N0TE95% CI PE - 3759 - 3754 no data Venous thromboembolism or death 132 1914 166 1956 0,81[0,64; 1,03] VTE 132 1914 166 1956 0,81[0,64; 1,03] fatal PE - 3759 - 3754 no data DVT - 3759 - 3754 no data proximal deep-vein thrombosis 132 3759 166 3754 0,79[0,63; 1,00] Asymptomatic deep vein thrombosis during follow-up. - 3759 - 3754 no data Major bleeding during follow-up - 3759 - 3754 1,19[0,67; 2,12] Symptomatic deep vein thrombosis during follow-up - 3759 - 3754 0,81[0,65; 1,00] All-cause death during follow-up - 3759 - 3754 no data Symptomatic pulmonary embolism during follow-up 132 3759 166 3754 0,79[0,63; 1,00] net clinical benefit 141 1914 174 1956 0,83[0,66; 1,04] Clinically relevant bleeding - 3759 - 3754 no data0,22,01,0

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016 May 27;:     [PMID: 27232649]   link to pdf   add to Mendeley  

ClinicalTrial.gov record NCT01583218



Registering number NCT01583218 (see trial on clinicaltrials.gov)
Code Name